Copper ion complex based on protein template as well as preparation method and application of copper ion complex
Through the copper ion complex based on the protein template, Cu2+ is complexed in situ with the copper ion carrier through the protein template, the problems of poor solubility and low bioavailability of existing copper ion complexes are solved, and efficient and long-lasting therapeutic effects are achieved.
Patent Information
- Application Number
- CN202510267667.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-03-07
- Publication Date
- 2025-06-10
AI Technical Summary
The existing copper ion complexes have poor solubility and low bioavailability, resulting in poor treatment effect and toxic side effects.
The copper ion complex based on the protein template is used to complex Cu2+ in situ through the protein template with the copper ion carrier to form a nano-scale copper ion complex with uniform morphology and good water solubility.
It improves the solubility and bioavailability of copper ion complexes, and achieves high efficacy, small toxic side effects, long-lasting effects and good stability.
Smart Images

Figure CN120114610A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a copper ion complex, in particular to a protein template-based copper ion complex, and also relates to a preparation method and application of the above copper ion complex. Background Art
[0002] Copper is an essential trace element that exists in both oxidized and reduced forms and plays a key role in various biological processes such as redox chemistry, enzyme reactions, mitochondrial respiration, iron metabolism, autophagy, and immune regulation. For example, copper is a cofactor for key enzymes, including cytochrome c oxidase, which is an essential component of the mitochondrial electron transport chain and is required for cell respiration and energy production. In addition, copper can regulate cell growth and function. Insufficient copper content can lead to growth inhibition, while excessive copper exposure can induce a new type of regulated cell death called cuproptosis, resulting in oxidative stress, cell death, and tissue damage.
[0003] Therefore, based on copper overload, forming copper ion complex drugs by copper ion carriers and additional copper agents to cause abnormal accumulation of copper ions in cells to induce cuproptosis is a new idea for antibacterial or tumor treatment. Disulfiram (DSF) is a well-known copper ion carrier with potential antibacterial and antitumor activities. Diethylcarbamodithioate (DDC) is a metabolite of DSF and can complex with Cu2 + to generate the copper ion complex copper diethyldithiocarbamate (Cu(DDC) 2 ), which is the drug active ingredient for the DSF / Cu combination therapy to exert its effect.
[0004] However, most current copper ion complex drugs such as Cu(DDC) 2 have poor solubility and are difficult to administer directly. In many studies including clinical trials, DSF and Cu 2+ are administered in combination with different formulations. However, DSF is rapidly metabolized and degraded in vivo, resulting in a low concentration of Cu(DDC) 2 at the treatment site and little effect. Several different nano-drug formulations (such as solid nanoparticles, liposomes, and micelles) have been used to improve the solubility of copper ion complexes, and there are still some problems to be overcome: (1) The drug loading capacity is often low, and the preparation and purification processes are relatively complex, with high production costs and complex preparation processes, which are not suitable for large-scale production; (2) The drug release of many formulations is slow or incomplete, and only a low drug concentration can be achieved, making it difficult to obtain the minimum drug concentration for clinical use. Due to the lack of suitable formulations, the clinical application of copper ion complexes is very limited. Therefore, there is an urgent need to develop a general method for preparing copper ion complexes suitable for clinical use. Summary of the Invention
[0005] Objective of the Invention: The objective of the present invention is to provide a protein-template-based copper ion complex with good solubility and high bioavailability, and also to provide a preparation method and application of the above copper ion complex.
[0006] Technical Solution: The present invention discloses a protein-template-based copper ion complex. The complex uses a protein template as a carrier and in-situ complexes Cu with a copper ion carrier 2+ , to obtain a nanoscale copper ion complex with uniform morphology and good water solubility. The protein template is bovine serum albumin (BSA) or human serum albumin (HSA); the copper ion carrier is sodium diethyldithiocarbamate (DDC-Na), naphthazarin (NAP), quercetin (QUE) or ilisomide.
[0007] Among them, the mass ratio of the protein template, the copper ion carrier, and Cu 2+ is 1 - 40 mg : 5 - 50 mg : 20 - 200 mg.
[0008] Among them, the copper ion complex is Cu(DDC) 2 -BSA, Cu(NAP) 2 -BSA, Cu(QUE) 2 -BSA, Cu(DDC) 2 / Au-BSA.
[0009] Among them, it is further preferably that the protein template as the carrier is modified with gold nanoparticles to synthesize a copper ion complex with enzyme-like activity; the enzyme-like activity is catalase-like or glucose oxidase-like.
[0010] The preparation method of the above protein-template-based copper ion complex includes the following steps: Prepared by a one-step method. Take the protein template or the protein template modified with gold nanoparticles, dissolve it in water, add an aqueous solution of Cu 2+ and stir to react. Under continuous stirring, add the copper ion carrier and continue to react. After the reaction ends, the protein-template-based copper ion complex is obtained.
[0011] Among them, the method for preparing the protein template modified with gold nanoparticles is: Dissolve the protein template and HAuCl 4 in water. Under continuous stirring, add an aqueous solution of NaBH 4 , and continuously stir for 0.5 - 3 hours to obtain the protein template modified with gold nanoparticles.
[0012] Among them, the mass ratio of the protein template, HAuCl 4 and NaBH 4 is 10 : 1 : 1 - 100 : 1 : 1.
[0013] Among them, Cu2+ The aqueous solution is CuCl₂·2H 2 O aqueous solution.
[0014] Among them, for the stirring reaction, the time is 1 - 1.5 h, and for the continuous reaction, the time is 0.5 - 3 h, and the temperature is room temperature.
[0015] The above protein template-based copper ion complex can also be applied in the preparation of anti-tumor and / or antibacterial drugs.
[0016] Principle of the invention: For the protein template-based copper ion complex of the present invention, by using the protein template as a carrier to stabilize the copper ion carrier and in-situ complexing Cu with the copper ion carrier 2+ , a copper ion complex with good solubility and high bioavailability is obtained. Therefore, the formed copper ion complex has advantages such as high drug efficacy, small toxic and side effects, long-lasting action, and good stability. Most proteins such as albumin have a high binding constant with copper and can be used as an isolator for copper and Cu 2+ . The interaction between the protein and metal ions enhances its thermal activity, biological activity, and adsorption activity. Structurally, the protein has an external hydrophilic domain with a hydrophobic core, which provides a great opportunity to adjust its geometry from 0D to 3D materials. Copper and Cu 2+ are wrapped and adsorbed in the protein matrix through electrostatic interaction and further in-situ complexed with the copper ion carrier. Due to the high water solubility and stability of the protein template, it can effectively stabilize the in-situ formed copper ion complex and prevent the formation of large aggregates. Directly delivering the copper ion complex drug can avoid the problem of rapid metabolism and degradation of the copper ion carrier in the body after separately administering the copper ion carrier and Cu 2+ , improve the copper ion complex drug at the treatment site while reducing the dosage, thereby improving the bioavailability, increasing the effect, and reducing a series of toxic and side effects caused by excessive drug concentration. It should be noted that some modified protein carriers such as albumin can be used as targeting ligands to bind to the albumin-binding protein (such as SPARC) overexpressed in tumor cells to further improve the bioavailability.
[0017] Beneficial effects: Compared with the prior art, the present invention has the following remarkable advantages: (1) The protein template-based copper ion complex of the present invention has strong solubility and good stability. Compared with water-insoluble Cu(DDC) 2 , the copper ion complex Cu(DDC) synthesized by the method of the present invention 2-BSA can be stably stored at room temperature for at least 30 days, and it has high efficacy and a long-lasting effect. It not only has good anti-tumor effects but also has antibacterial and antifungal effects. At the same time, it will not cause hemolysis of blood cells at concentrations higher than the effective treatment concentration; (2) The preparation method of the complex of the present invention adopts a one-step green synthesis technology. The mild synthesis conditions avoid the use of organic solvents and do not require large-scale instruments, greatly saving the synthesis cost, being suitable for popularization, and being applicable to a variety of copper ion carriers. Its formula and preparation process are simple, suitable for large-scale production preparation processes, and have the potential to achieve clinical transformation and commercialization in the future. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 is the particle size of Cu(DDC) 2 -BSA;
[0019] Figure 2 is the particle size of Cu(NAP) 2 -BSA;
[0020] Figure 3 is the particle size of Cu(QUE) 2 -BSA;
[0021] Figure 4 is the particle size of Cu(DDC) 2 / Au-BSA;
[0022] Figure 5 is the particle size of Cu(DDC) 2 -BSA TEM image;
[0023] Figure 6 is the particle size of Cu(NAP) 2 -BSA SEM image;
[0024] Figure 7 is the particle size of Cu(DDC) 2 -BSA anti-Candida albicans result;
[0025] Figure 8 is the particle size of Cu(NAP) 2 -BSA anti-Staphylococcus aureus result;
[0026] Figure 9 is the particle size of Cu(DDC) 2 -BSA and Cu(DDC) 2 / Au-BSA anti-tumor effect comparison;
[0027] Figure 10 is the particle size of Cu(QUE) 2 -BSA anti-tumor result;
[0028] Figure 11 is the particle size of Cu(NAP)2 -BSA's blood compatibility;
[0029] Figure 12 is Cu(DDC) 2 / Au-BSA's blood compatibility;
[0030] Figure 13 is Cu(DDC) 2 / Au-BSA's long-term stability results. Specific implementation manners
[0031] The technical solutions of the present invention will be further described below in conjunction with embodiments. The test materials used in the embodiments can be obtained through conventional channels.
[0032] Embodiment 1
[0033] The protein template-based copper ion complex Cu(DDC) 2 -BSA of the present invention, and its preparation method includes the following steps:
[0034] Dissolve 1-40 mg of BSA in 1-20 ml of ultrapure water. Then, add 1-10 mL of CuCl₂·2H 2 O aqueous solution (5 mg / mL) to the reaction mixture for 1 hour, and quickly add 1-10 mL of DDC-Na aqueous solution (20 mg / mL) to the reaction mixture under continuous stirring. After reacting for 0.5-3 hours, the protein template-based copper ion complex Cu(DDC) 2 -BSA is obtained.
[0035] Embodiment 2
[0036] The protein template-based copper ion complex Cu(NAP) 2 -BSA of the present invention, and its preparation method includes the following steps:
[0037] Dissolve 1-40 mg of BSA in 1-20 ml of ultrapure water. Then, add 1-10 mL of CuCl₂·2H 2 O aqueous solution (5 mg / mL) to the reaction mixture for 1 hour, and quickly add 1-10 mL of NAP aqueous solution (20 mg / mL) to the reaction mixture under continuous stirring. After reacting for 0.5-3 hours, the protein template-based copper ion complex Cu(NAP) 2 -BSA is obtained.
[0038] Embodiment 3
[0039] The protein template-based copper ion complex Cu(QUE) 2 -BSA of the present invention, and its preparation method includes the following steps:
[0040] Dissolve 1 - 40 mg of BSA in 1 - 20 ml of ultrapure water. Then, add 1 - 10 ml of an aqueous CuCl₂·H 2 ₂O solution (5 mg / mL) to the reaction mixture for 1 hour, and rapidly add 1 - 10 ml of an aqueous QUE solution (20 mg / mL) to the reaction mixture with continuous stirring. After reacting for 0.5 - 3 hours, the protein template-based copper ion complex Cu(QUE) 2 -BSA is obtained.
[0041] Example 4
[0042] The protein template-based copper ion complex Cu(DDC) 2 / Au-BSA of the present invention, and its preparation method includes the following steps:
[0043] Dissolve 1 - 40 mg of BSA and 1 - 10 mg of HAuCl 4 ₄ in 1 - 20 ml of ultrapure water. Then, with continuous stirring, rapidly add 100 μL of an aqueous NaBH 4 ₄ solution (1 - 10 mg / mL) to the mixture solution, and continuously stir for 0.5 - 3 hours. Then, add 1 - 10 ml of an aqueous CuCl₂·H 2 ₂O solution (5 mg / mL) to the reaction mixture for 1 hour, and rapidly add 1 - 10 ml of an aqueous DDC-Na solution (20 mg / mL) to the reaction mixture with continuous stirring. After reacting for 0.5 - 3 hours, the protein template-based copper ion complex Cu(DDC) 2 / Au-BSA is obtained.
[0044] Example 5
[0045] Determination of the particle size, ZETA potential and morphology of the copper ion complex drug:
[0046] The particle size and zeta potential were measured by Malvern Nano ZS according to the dynamic light scattering method to measure the particle size and polydispersity index (PDI). The copper ion complex drug was diluted with water before measurement. The particle size was measured at a scattering angle of 173 degrees. In addition, the zeta potential was also measured using Malvern Nano ZS.
[0047] When characterizing the copper ion complex drug by transmission electron microscopy (TEM), first add the sample to the grid, and then perform uranyl acetate staining. Then observe the sample on a JEOL 2000EX transmission electron microscope.
[0048] The results are as Figures 1 to 4 shown, which are the particle sizes of the protein template-based copper ion complexes prepared in Examples 1 - 4, and their particle sizes are all less than 100 nm; asFigure 5 As shown, it is Cu(DDC) 2 -BSA TEM image, which is the morphology of a metal ion complex in nanosize; as Figure 6 shown, it is Cu(NAP) 2 -BSA SEM image, which is in nanosize, evenly dispersed, and of uniform size.
[0049] Example 6
[0050] Copper ion complex drug Cu(DDC) 2 / Au-BSA long-term stability test:
[0051] To determine the long-term stability of the copper ion complex drug Cu(DDC) 2 / Au-BSA, it was continuously placed at room temperature for 30 days, and its long-term storage stability was determined by particle size change at different time points during this period.
[0052] The results are as Figure 13 shown. Even after being placed at room temperature for 30 days, the hydrodynamic diameter of the copper ion complex drug Cu(DDC) 2 / Au-BSA did not change significantly compared with that on the first day, and its particle size remained at about 80 nm, indicating that it can be placed at room temperature for at least 30 days.
[0053] Example 7
[0054] Copper ion complex drug Cu(DDC) 2 -BSA Candida albicans antibacterial activity test:
[0055] The anti-Candida albicans activity of Cu(DDC) 2 -BSA was tested by the microbroth dilution method. Candida albicans was diluted into a working solution with Sabouraud dextrose broth (SDB) after overnight culture, and the working concentration was 2.5×10 3 CFU / mL. Using the Cu 2 + concentration as the standard, Cu(DDC) 2 -BSA was serially diluted with SDB in a 96-well plate, and the concentration range was from 0.325 μg / mL to 5 μg / mL. The control group was the same volume of SDB. Subsequently, the same volume of the Candida albicans working solution was added and co-incubated in a bacterial incubator at 37°C for 16 h. The absorbance of each well was measured at a wavelength of 600 nm using a microplate reader (SpectraMax i3x, Molecular Devices).
[0056] The results are as Figure 7As shown, when the copper concentration is 1.25 μg / mL, the inhibition rate exceeds 90%, and when it is 2.5 μg / mL, the inhibition rate exceeds 99%, showing an obvious concentration-dependent toxic effect on Candida albicans.
[0057] Example 8
[0058] Copper ion complex drug Cu(NAP) 2 -BSA antibacterial activity test against Staphylococcus aureus
[0059] The anti-Staphylococcus aureus activity of Cu(NAP) 2 -BSA was tested by the plate spreading method and the microtiter plate method. After Staphylococcus aureus was cultured to the logarithmic growth phase, it was diluted into a working solution with LB liquid medium, and the working concentration was 3×10 5 CFU / mL. Using the copper 2+ concentration as the standard, Cu(NAP) 2 -BSA was serially diluted with LB liquid medium in a 96-well plate, and the concentration range was 1 μg / mL to 2.5 μg / mL. The control group was the same volume of LB liquid medium. Subsequently, the same volume of the Staphylococcus aureus working solution was added and incubated in a bacterial incubator at 37°C for 16 h. 100 μL of the bacterial solution was taken from each well and serially diluted by a factor of 10. 10 μL of the serially diluted bacterial solution was successively spotted onto the LB solid medium. After the bacterial solution was fully absorbed, it was incubated upside down in a bacterial incubator at 37°C for 24 h to record the colony growth. 100 μL of the bacterial solution with an appropriate dilution factor was added to the LB solid plate and spread evenly, and the colony number was recorded after incubating upside down in a bacterial incubator at 37°C for 24 h.
[0060] The results are as Figure 8 shown. Compared with the control group, when the copper concentration was 1.875 μg / mL, no obvious Staphylococcus aureus colonies could be seen on the LB plate. At the same time, as the copper concentration increased, its inhibitory effect on Staphylococcus aureus was better, showing a concentration-dependent antibacterial ability.
[0061] Example 9
[0062] Copper ion complex drug Cu(DDC) 2 -BSA and Cu(DDC) 2 / Au-BSA antitumor activity comparison:
[0063] The MTT assay was used to detect the toxicity of Cu(DDC) 2 -BSA and Cu(DDC) 2 / Au-BSA on the cancer cell HepG2. Cells were seeded in a 96-well plate at a density of 10,000 cells per well. After culturing for 12 hours, the cells were treated with the specified concentration of Cu(DDC) 2-BSA and Cu(DDC) 2 Treat with / Au-BSA for 24 hours. Then, add 10 μL (5 mg / mL) of MTT to each well of the plate. After culturing for 4 hours, remove the MTT solution and add 150 μL of DMSO to dissolve the formazan crystals. Measure the absorbance of each well at a wavelength of 490 nm using a microplate reader (SpectraMax i3x, Molecular Devices).
[0064] The results are as Figure 9 shown. Whether it is the copper ion complex drug Cu(DDC) 2 -BSA or the composite copper ion complex drug Cu(DDC) 2 / Au-BSA, both show a dose-dependent antitumor effect.
[0065] Example 10
[0066] Antitumor activity test of the copper ion complex drug Cu(QUE) 2 -BSA:
[0067] The MTT assay was used to detect the toxicity of Cu(QUE) 2 -BSA to cancer cells 4T1. Cells were seeded in 96-well plates at a density of 10,000 cells per well. After culturing for 12 hours, treat with the specified concentration of Cu(QUE) 2 -BSA for 24 hours. Then, add 10 μL (5 mg / mL) of MTT to each well of the plate. After culturing for 4 hours, remove the MTT solution and add 150 μL of DMSO to dissolve the formazan crystals. Measure the absorbance of each well at a wavelength of 490 nm using a microplate reader (SpectraMax i3x, Molecular Devices).
[0068] The results are as Figure 10 shown. The copper ion complex drug Cu(QUE) 2 -BSA shows a dose-dependent antitumor effect, and its IC50 is about 15 μg / mL.
[0069] Example 11
[0070] Blood compatibility test of the copper ion complex drugs Cu(DDC) 2 -BSA and Cu(NAP) 2 -BSA:
[0071] Take the blood of healthy rabbits and prepare a 4% erythrocyte suspension with 0.9% sodium chloride solution. Add 800 μL of water to 200 μL of 4% erythrocyte suspension as the positive control, add 800 μL of PBS to 200 μL of 4% erythrocyte suspension as the negative control, and add 800 μL of Cu(NAP) with a specified concentration to 200 μL of 4% erythrocyte suspension 2 -BSA as the experimental group. After treatment for 3 hours, take the supernatant and measure the absorbance of each supernatant at a wavelength of 540 nm using a microplate reader (SpectraMax i3x, Molecular Devices).
[0072] Example 12
[0073] Copper ion complex drug Cu(DDC) 2 / Au-BSA blood compatibility test:
[0074] Take the blood of healthy rabbits and prepare a 4% erythrocyte suspension with 0.9% sodium chloride solution. Add 800 μL of water to 200 μL of 4% erythrocyte suspension as the positive control, add 800 μL of PBS to 200 μL of 4% erythrocyte suspension as the negative control, and add 800 μL of Cu(DDC) with a specified concentration to 200 μL of 4% erythrocyte suspension 2 / Au-BSA as the experimental group. After culturing for 3 hours, centrifuge to obtain the supernatant and measure the absorbance of each supernatant at a wavelength of 540 nm using a microplate reader (SpectraMax i3x, Molecular Devices).
[0075] The results are as Figure 11 and 12 shown. Even when the copper ion concentration is as high as 100 μg / mL, the hemolysis rate of rabbit erythrocytes does not reach 10%, showing good blood compatibility.
[0076] Therefore, the protein template-based copper ion complex of the present invention solves the problems of poor solubility and low bioavailability of existing copper ion complexes, achieving the effects of high drug efficacy, small toxic and side effects, long-lasting action, and good stability; its preparation method has a simple process and mild conditions, and is suitable for large-scale production; the protein template-based copper ion complex has extremely strong anti-tumor and antibacterial activities when applied in the preparation of anti-tumor and / or antibacterial drugs, and has great clinical application prospects.
Claims
1. A copper ion complex based on a protein template, characterized in that: The copper ion complex uses the protein template as a carrier and in situ complexes Cu with the copper ion carrier. 2+ The protein template is bovine serum albumin or human serum albumin, and the copper ion carrier is sodium diethyldithiocarbamate, naphthane, quercetin or ilisimol.
2. The copper ion complex according to claim 1, characterized in that Protein template, copper ion carrier, Cu 2+ The mass ratio is 1-40mg:5-50mg:20-200mg.
3. The copper ion complex according to claim 1, characterized in that The protein template used as a carrier is modified with gold nanoparticles to synthesize a copper ion complex with enzyme-like activity.
4. The copper ion complex according to claim 3, characterized in that The enzyme-like activity is catalase-like or glucose oxidase-like.
5. A method for preparing the copper ion complex based on protein template according to claim 1, characterized in that: The steps include: taking a protein template or a protein template modified with gold nanoparticles, dissolving it in water, adding Cu 2+ The aqueous solution is stirred for reaction, and the copper ion carrier is added under continuous stirring and the reaction is continued. When the reaction is completed, a copper ion complex based on a protein template is obtained.
6. The copper ion complex according to claim 5, characterized in that The gold nanoparticle-modified protein template is prepared by dissolving the protein template and HAuCl4 in water, adding a NaBH4 aqueous solution under constant stirring, and continuing stirring for 0.5 to 3 hours to obtain the gold nanoparticle-modified protein template.
7. The copper ion complex according to claim 6, characterized in that The mass ratio of protein template, HAuCl4 and NaBH4 is 10:1:1 to 100:1:
1.
8. The copper ion complex according to claim 5, characterized in that Cu 2+ The aqueous solution is CuCl2H2O aqueous solution.
9. The preparation method according to claim 5, characterized in that: The stirring reaction is carried out for 1 to 1.5 hours, the continued reaction is carried out for 0.5 to 3 hours, and the temperature is room temperature.
10. Use of the protein template-based copper ion complex according to claim 1 in the preparation of anti-tumor and / or antibacterial drugs.
Citation Information
Cited By
Nano protein drug combined with metal ions and preparation method and application thereof
CN120585786A
Metal ion-associated nanoprotein drug and preparation method and use thereof
CN120585786B
